Low-grade glioma
Conditions
Interventions
Radiotherapy alone group:IMRT (54Gy/30f)
Radiotherapy combined with temozolomide concurrent and adjuvant chemotherapy group:IMRT (54Gy/30f)+ temozolomide concurrent chemotherapy + temozolomide adjuvant chemotherapy
Sponsors
Department of Oncology, Xiangya Hospital,Central South University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Incomplete High-risk low-grade gliomas after incomplete resection, or IDH wild-type, or = 3 risk factors (age =40y, stellate origin, bilateral hemispheres, diameter > 6cm, preoperative neurological deficit > 1non-1p19q deletion) (WHO Level II) patients; 2. Patients who have not been treated with radiotherapy or chemotherapy previously; 3. Male or female aged 18-60 years; 4. Liver function: Total bilirubin = normal value upper limit (ULN), AST and alt = 2.5 times normal value upper limit (ULN), alkaline phosphatase = 5 times times normal value upper limit (ULN); 5. Renal function: Creatinine clearance rate =80 ml/min; 6. Blood test: Absolute neutrophil count (ANC) =2x10^9/L, platelet count =100x10^9/L and hemoglobin =9g/dl; 7. KPS score =80; 8. Signed Informed consent.
Exclusion criteria
Exclusion criteria: 1. Have been treated with anti-tumor therapy, including chemotherapy and radiotherapy; 2. Women in pregnancy or lactation; 3. Patients not cooperating with regular follow-up due to psychological, social, family and geographic reasons; 4. Known to be allergic to chemotherapeutic drugs that may be used; 5. With a severe uncontrolled infection or medical illness; 6. Major organ dysfunction, such as decompensated heart, lung, kidney, liver failure, can not tolerate radiotherapy and chemotherapy; 7. Laboratory examination: Total bilirubin > normal value upper limit (ULN), AST and/or ALT > 1.5 times normal value upper limit (ULN) and accompanied by alkaline phosphatase 2.5 times times normal value upper limit (ULN); 8. Has the fator to influence the medicine, the distribution, the metabolism, the excretion, such as the central nervous system abnormality, the chronic diarrhea, the ascites, the chest water and so on; 9. Long-term use of immunosuppressive agents after organ transplantation; 10. There is a history of other malignant tumors before the study. 11. Patients with targeted drug therapy; 12. With history of other malignancies; 13. With serious heart, lung and other important organ dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;objective response rate; | — |
Countries
China
Contacts
Public ContactLiangfang Shen
Department of Oncology, Xiangya Hospital, Central South University
Outcome results
None listed